profit from every $100 of sales.
$0$100
BioNTech
$87.65+0.50% today
-19.3% in 1 year
1-year low $83.891-year high $119.34
Trading close to its lowest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2022 to 2025.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
It holds more cash than debt.
No debt5 years
Money in, money out
What BioNTech sold, what it kept, and what it did with the cash.
Sales went from €17.3 billion in 2022 to €2.87 billion in 2025, with -€1.14 billion of profit last year.
SalesProfit
BioNTech vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| BioNTech | No profit yet | ||
 Vertex Pharmaceuticals | 35.1× · Expensive | ||
 Moderna | No profit yet | ||
 Regeneron Pharmaceuticals | 22.0× · Fair price | ||
 CSL | 22.1× · Fair price |
AI analysis
An AI analyst reads BioNTech's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of EUR | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 17,311 | 3,819 | 2,751 | 2,870 | |
| 14,316 | 3,219 | 2,210 | 2,228 | |
| 12,304 | 876 | -709 | -641 | |
| 13,096 | 1,377 | -363 | -654 | |
| 9,434 | 930 | -665 | -1,136 | |
| 37.77 | 3.83 | -2.77 | -4.70 | |
| 82.7% | 84.3% | 80.3% | 77.6% | |
| 71.1% | 22.9% | -25.8% | -22.3% | |
| 54.5% | 24.4% | -24.2% | -39.6% |
Balance sheet
| In millions of EUR | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 23,279 | 23,006 | 22,530 | 21,989 |
| Cash | 13,875 | 11,664 | 9,762 | 7,675 |
| Total debt | 212 | 219 | 254 | 267 |
| Total liabilities | 3,224 | 2,760 | 3,119 | 2,764 |
| 20,056 | 20,246 | 19,411 | 19,224 | |
| 250 | 243 | 240 | 242 | |
| 50.6% | 4.6% | -2.7% | -4.2% | |
| 47.0% | 4.6% | -3.4% | -5.9% |
Cash flow
| In millions of EUR | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 13,577 | 5,371 | 208 | 456 | |
| 363 | 706 | 452 | 749 | |
| 13,214 | 4,666 | -245 | -293 | |
| Dividends paid | 484 | 0 | 0 | – |
| 986 | 739 | 0 | 0 | |
| 109 | 51 | 101 | 106 |
Valuation
- –
- –
- –
- 1.1×
- 6.8×
- –
- –
- -1.5%
- -5.8%
- 0.0%
Profitability
- 77.6%
- -22.3%
- -39.6%
- -25.1%
- -7.5%
- 25.3%
- -6.7%
- -5.9%
- -7.5%
- 76.2%
Growth
- −45.1%
- –
- +210.3%
- –
- −0.2%
Financial health
- -11.3×
- 0.02
- 1.4%
- -67.9×
- 8.80
- 8.74
- 0.13
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 26%of 958
Bottom 11%of 889
Bottom 2%of 890
Bottom 30%of 987
What analysts expect
- Average price target
- $137.13
- Range
- $113.00 – $155.00
- 5 analysts
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 5, 2026 | -2.28 | -2.52 | +9.5% |
| Mar 10, 2026 | -0.38 | -0.22 | −72.7% |
| Nov 3, 2025 | -0.14 | -1.12 | +87.5% |
| Aug 4, 2025 | -1.82 | -2.69 | +32.3% |
| May 5, 2025 | -1.82 | -2.48 | +26.5% |
| Mar 10, 2025 | 1.15 | 0.46 | +148.7% |
| Nov 4, 2024 | 0.89 | -1.74 | +151.1% |
| Aug 5, 2024 | -3.62 | -2.19 | −65.2% |
News
BioNTech beats top-line and bottom-line estimates; raises FY26 outlookSeeking Alpha · Nov 3, 2026Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
1/7Passes 1 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
38No pass
Benjamin Graham
68Pass
Philip Fisher
52No pass
Peter Lynch
30No pass
Joel Greenblatt
2No pass
Charlie Munger
56No pass
Terry Smith
45No pass
Questions about BioNTech
Is BioNTech a good stock to buy?
A business with weak numbers that is not profitable yet. 1 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the BioNTech AI analysis
What does BioNTech do?
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. It is in Biotechnology, based in Mainz, Germany, with 7,807 employees.
Does BioNTech pay a dividend?
No. BioNTech does not pay a dividend at the moment.
Is BioNTech stock halal?
No. BioNTech does not pass our halal screen: its cash and confirmed interest-bearing investments are 39% of its market value, at or above the 33% limit. How we check
How has BioNTech stock done over the past year?
Down 19.3% over the past twelve months, to $87.65. It traded between $83.89 and $119.34 and is 26.6% below its high.
Who are BioNTech's competitors?
The largest listed companies in the same industry are Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals and CSL. The peers table on this page compares their profit, growth and price with BioNTech's.
Prices: daily closes to Nov 11, 2026. Fundamentals: company reports via invest-like data.